AbbVie's drug ustekinumab is being submitted for approval for a new indication in China.

According to the financial information APP, on September 23rd, the website of the Center for Drug Evaluation (CDE) showed that AbbVie's epcoritamab injection was applied for a new indication in China. According to the progress of priority review, the indication for this application is for the treatment of relapsed or refractory follicular lymphoma (FL) in adult patients in combination with rituximab and lenalidomide.